Malmö, November 14, 2019
Acarix finalized a rights issue to finance further market expansion
In September we announced a rights issue in order to be able to further develop our product offering and to intensify our international investments. During this period, I had the opportunity to present Acarix at a large number of events, creating interest and increased awareness of our company and unique CADScor®System.
Extract from CEO Per Persson’s message to the Interim Report.
Third quarter 2019 compared with same period 2018
First nine months 2019 compared with same period 2018
Events in the third quarter, 2019
Events after September 30, 2019
·On October 30 the final outcome in the Rights Issue was announced. Totally 19,664,038 shares, corresponding to approximately 56.9 percent of the offered shares, had been subscribed for with and without the use of subscription rights. A total guarantee of 9,002,629 shares, corresponding to approximately 26.0 percent of the Rights Issue will be utilized. The board of directors has in accordance with adopted principles for allotment, thus allotted 28,666,667 offered shares in the Rights Issue. The Rights Issue provides the Company with approximately SEK 43 million before deduction of transaction costs.
The complete interim report is available by link below or on www.acarix.com
For further information, please contact:
Per Persson, CEO
mail: per.persson@acarix.comtel:
+46 736 005 990
Christian Lindholm, CFO
mail: christian.lindholm@acarix.com
tel: +46 705 118 333
About Acarix
Acarix was established in 2009 and is listed on Nasdaq First North Premier. Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed and displayed as a patient specific score, the CAD score, on the device screen. Readings are obtained in less than 8 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor®System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful and invasive diagnostic procedures.
The information disclosed above is mandatory for Acarix AB (publ) to publish pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of the above contact person on September 14, 2019 at 8:00 am (CET).
Attachments